Eli Lilly will buy AtaiBeckley for up to $3.8 billion, the company said on Thursday, joining a race among pharma majors to develop psychedelic treatments for depression and other mental health disorders.
Interest in the sector received a boost after U.S. President Donald Trump in April directed health regulators to speed up reviews of certain psychedelic treatments and increased federal funding for research in the field.